Law360, Washington (June 26, 2012, 6:46 PM ET) -- As the U.S. Food and Drug Administration prepares to issue a decision on Arena Pharmaceuticals Inc.'s lorcaserin, watchdog group Public Citizen Inc. urged the agency on Tuesday not to allow the weight-loss drug to hit the market, citing heart valve concerns.
The Public Citizen letter, addressed to FDA Commissioner Margaret Hamburg, noted that the FDA's Endocrinologic and Metabolic Drugs Advisory Committee had serious reservations when it recommended lorcaserin for FDA approval in May. The drug had previously failed to gain committee support in 2010 after a...
Public Citizen Pushes FDA To Deny Diet Pill Approval
To view the full article, take a free trial now.
